• Separating Growth Inhibition from Cancer Cell Killing

  2026-09-16

  Hannah R. Schwartz’s dissertation shows that relative viability and fractional viability capture different dimensions of in vitro drug response: composite growth suppression versus actual cell killing. Its central implication is that cancer drug screens should separate proliferation arrest from death and account for their distinct proportions and timing when interpreting efficacy.

• 4-Phenylbutyric Acid in ER Stress Models

  2026-09-15

  4-Phenylbutyric acid provides a practical chemical-chaperone strategy for testing whether ER stress contributes to toxicant-induced injury. This workflow connects UPR profiling with ferroptosis, apoptosis research, and cell-survival assays while preserving the distinctions between pathway modulation and proof of causality.

• MK-8745: Aurora A Inhibitor Workflow

  2026-09-15

  Build a practical MK-8745 workflow for measuring mitotic arrest, tetraploidy, and apoptosis in cancer models. The approach connects a potent, selective Aurora A inhibitor to retinoblastoma biology, non-Hodgkin lymphoma studies, and tumor xenograft hypotheses while keeping assay interpretation and formulation controls explicit.

• Deep Learning Detects Cardiotoxicity in iPSC-CMs

  2026-09-14

  The eLife study combined human induced pluripotent stem cell-derived cardiomyocytes, high-content imaging, and deep learning to identify cardiotoxic phenotypes across compound libraries. Its single-parameter screening score offers an efficient early-stage triage strategy, while still requiring orthogonal electrophysiological and mechanistic validation.

• Dihydroartemisinin: Choosing the Right Assay

  2026-09-14

  Dihydroartemisinin is an Artemisia plant extract-derived research compound with antimalarial, mTOR, psoriasis, and inflammation applications. This guide builds an evidence-based assay strategy that separates direct product evidence from useful but indirect antiplasmodial comparator data.

• N1-Methylpseudo-UTP for mRNA Workflows

  2026-09-13

  Build more stable, translationally reliable RNA with N1-Methyl-Pseudouridine-5'-Triphosphate in controlled in vitro transcription workflows. This guide connects reagent handling, assay design, translation-fidelity controls, and troubleshooting for mRNA therapeutics and RNA mechanism studies.

• Nerve-Dependent HDAC1 in Axolotl Regeneration

  2026-09-12

  Wang and colleagues show that nerve-dependent HDAC1 elevation is required for blastema formation and successful limb regeneration in axolotls. Pharmacological inhibition, denervation, and growth-factor rescue experiments position HDAC1 activity in the wound epidermis as an important epigenetic link between nerve signaling and regenerative competence.

• Gut Dysbiosis, LPS, and STAT3 in Prostate Cancer

  2026-09-11

  Zhong et al. identified a contact-independent mechanism connecting antibiotic-associated gut dysbiosis with prostate cancer progression and docetaxel resistance through intratumoral LPS and the NF-κB–IL6–STAT3 axis. The study combines mouse models, fecal microbiota transplantation, 16S rRNA profiling, mechanistic cell experiments, and patient data to link Proteobacteria enrichment with metastatic disease.

• Aurora A Overexpression in Retinoblastoma

  2026-09-11

  A 2024 American Journal of Pathology study identifies AURKA overexpression as a clinically relevant feature of human retinoblastoma and links it to histopathologic high-risk factors. By combining patient-tissue profiling with genetic depletion, pharmacologic inhibition, patient-derived material, and xenograft models, the work supports AURKA as a therapeutic vulnerability while highlighting its functional relationship with MYCN.

• Fluconazole Workflows for Candida Resistance

  2026-09-10

  Build reproducible Fluconazole assays for ergosterol disruption, susceptibility profiling, and Candida infection research. This guide connects practical stock handling with resistant-isolate comparisons and delayed-treatment study design.

• VX-745 in Reliable p38α MAPK Assays

  2026-09-10

  This scenario-based guide explains how VX-745, SKU A8686, can support reproducible studies of p38α MAPK signaling, cytokine secretion, proliferation, and cytotoxicity. It links biochemical potency with practical solvent handling, assay controls, interpretation, and evidence-aware product selection.

• SAG: Smoothened Receptor Agonist Workflows

  2026-09-09

  SAG provides a direct, controllable route to Smoothened activation for pathway assays, mechanistic rescue experiments, neurobiology models, and developmental studies. This guide connects product handling with the reference study’s ligand-versus-receptor assay logic, practical controls, and troubleshooting decisions.

• Verbascoside for PKC/NF-κB Assay Design

  2026-09-09

  Verbascoside provides a reversible small-molecule approach for dissecting PKC/NF-κB signaling in RANKL-driven osteoclastogenesis and related bone-cell models. This guide connects concentration planning, pathway readouts, and troubleshooting with a recent study of the TLR4/NF-κB/FGF21 axis in glucocorticoid-induced osteonecrosis.

• iPSC-Based Clinical Trial Selection for Ultrarare Disease

  2026-09-08

  Sequiera et al. developed a patient-specific iPSC platform to prescreen therapies for an ultrarare Leigh-like disorder caused by poorly characterized ECHS1 variants. The study shows how disease-relevant cellular models can connect genotype, functional drug response, and later clinical decision-making while reducing reliance on trial-and-error treatment.

• CBD in Orofacial Inflammatory Pain: Mechanisms

  2026-09-08

  This 2026 study shows that cannabidiol reduces both nociceptive and pain-related affective abnormalities in mouse models of orofacial and chronic inflammatory pain. Its main contribution is a multilevel mechanism linking peripheral FAAH and CB2 signaling with central CB1-dependent endocannabinoid activity and serotonin dynamics in the central amygdala.

8043 records 1/537 page Next 12345 下5页 Last page